Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: From the perspective of metastatic colorectal cancer patients in Japan

International Journal of Clinical Oncology

Volumn 15, Issue 3, 2010, Pages 256-262

  Shiroiwa, Takeru ^a   Fukuda, Takashi ^a   Tsutani, Kiichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Bevacizumab; Capecitabine; Colorectal neoplasms; Cost sharing; Cost effectiveness analysis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; INCOME; MEDICAL FEE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PUBLIC HEALTH INSURANCE; QUALITY ADJUSTED LIFE YEAR; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; DISEASE FREE SURVIVAL; ECONOMICS; FINANCIAL MANAGEMENT; JAPAN; MORTALITY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY; TIME; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; COST SHARING; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COSTS; FINANCING, PERSONAL; FLUOROURACIL; HUMANS; JAPAN; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; ANTIBODIES, MONOCLONAL, HUMANIZED;

EID: 77955711941     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0045-x     Document Type: Article

References (19)

1. Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352(5):476-487
2. Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 23(20):4553-4560
3. Hochster H, Hart L, Ramanathan R et al (2006) Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE study. J Clin Oncol 24:148S
4. Porschen R, Arkenau HT, Kubicka S et al (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 25(27):4217-4223
5. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al (2007) Phase III study of capecitabine plus oxaliplatin compared with continuous- infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25(27):4224-4230
6. Cassidy J, Clarke S, Diaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/ folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26(12):2006-2012
7. Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19(10):1720-1726
8. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938-2947
9. Giacchetti S, Perpoint B, Zidani R et al (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18(1):136-147
10. Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013-2019
11. Twelves C, Gollins S, Grieve R et al (2006) A randomised crossover trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 17(2):239-245
12. Shiroiwa T, Fukuda T, Tsutani K (2009) Health utility scores of colorectal cancer based on societal preference in Japan. Qual Life Res 18(8):1095-1103
13. Shiroiwa T, Fukuda T, Tsutani K (2009) Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. Br J Cancer 101(1):12-18
14. Social Insurance Research Laboratory (2009) Reimbursement schedule of social insurance for medical service fee. Social Insurance Research Laboratory, Tokyo
15. JIHO (2009) National health insurance drug price standard. JIHO, Tokyo
16. Lin D, Feuer E, Etzioni R et al (1997) Estimating medical costs from incomplete follow-up data. Biometrics 53:419-434
17. Shiroiwa T, Sung Y, Fukuda T et al (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ (in press)
18. Tappenden P, Jones R, Paisley S et al (2007) The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 43(17):2487-2494 (Pubitemid 350086932)
19. Shiroiwa T, Fukuda T, Tsutani K (2007) Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clin Ther 29(10):2256-2267